No products in the cart.
Rabbit Polyclonal ADAR1 antibody (STJ91483)
Supplier: St John’s Laboratory Ltd.
Recommended applications: IHC, ELISA
Recommended dilution: IHC 1:100-1:300; ELISA 1:20000;
Recommended protocols: check protocols
Click or hover above images to see image description for ADAR1 Polyclonal Antibody.
Check alternative names for the antibodyExpand
ADAR antibody, ADAR1 antibody, DSRAD antibody, G1P1 antibody, IFI4 antibody,|136 kDa double-stranded RNA-binding protein antibody|136kDa double stranded RNA binding protein antibody|Adar 1 antibody|ADAR antibody|Adar1 antibody|Adenosine deaminase acting on RNA 1 A antibody|Adenosine deaminase RNA specific 1 antibody|Adenosine deaminase RNA specific antibody|Adenosine deaminase that act on RNA antibody|AGS6 antibody|AV242451 antibody|Double stranded RNA specific adenosine deaminase antibody|Double-stranded RNA-specific adenosine deaminase antibody|Double-stranded RNA-specific editase Adar antibody|DRADA antibody|Dsh antibody|Dsrad antibody|DSRAD_HUMAN antibody|dsRNA adenosine deaminase antibody|EC 3.5.4.- antibody|G1P1 antibody|IFI 4 antibody|IFI-4 antibody|IFI4 antibody|Ifi4 protein antibody|Interferon induced protein 4 antibody|Interferon inducible protein 4 antibody|Interferon-inducible protein 4 antibody|K88DSRBP antibody|mZaADAR antibody|P136 antibody|Pre-mRNA adenosine deaminase antibody|RNA adenosine deaminase 1 antibody|RNA-editing deaminase 1 antibody|RNA-editing enzyme 1 antibody|Anti-ADAR1 antibody (ab88574)
SCBT cat No: sc-271854|
ADAR1 Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
ADAR1 Polyclonal Antibody detects endogenous levels of ADAR1 protein.
Synthesized peptide derived from ADAR1 at AA range 1140-1220
|Recommended dilution|| |
IHC 1:100-1:300; ELISA 1:20000;
|Molecular weight|| |
ADAR1 Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
ADAR1 Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Double-stranded RNA-specific adenosine deaminase antibody, DRADA antibody, 136 kDa double-stranded RNA-binding protein antibody, p136 antibody, Interferon-inducible protein 4 antibody, IFI-4 antibody, K88DSRBP antibody
|Protein names|| |
Double-stranded RNA-specific adenosine deaminase , DRADA , 136 kDa double-stranded RNA-binding protein , p136 , Interferon-inducible protein 4 , IFI-4 , K88DSRBP
|Protein function|| |
Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5’UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication. / Adenine in double-stranded RNA + H2O = hypoxanthine in double-stranded RNA + NH3.
|Protein tissue specificity|| |
Ubiquitously expressed, highest levels were found in brain and lung. Isoform 5 is expressed at higher levels in astrocytomas as compared to normal brain tissue and expression increases strikingly with the severity of the tumor, being higher in the most aggressive tumors.
|Involvement in disease|| |
Dyschromatosis symmetrica hereditaria (DSH) [MIM:127400]: An autosomal dominant pigmentary genodermatosis characterized by a mixture of hyperpigmented and hypopigmented macules distributed on the face and the dorsal parts of the hands and feet, that appear in infancy or early childhood. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Aicardi-Goutieres syndrome 6 (AGS6) [MIM:615010]: A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Contains 1 A to I editase domain. / Contains 2 DRADA repeats. / Contains 3 DRBM (double-stranded RNA-binding) domains.
|Protein post-translational modifications|| |
Sumoylation reduces RNA-editing activity.
|Protein cellular localization|| |
Cytoplasm / Nucleus / Cytoplasm / Nucleus / Nucleus > nucleolus
AntibodyPlus can customize ADAR1 Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: